EA202090850A1 - Способы лечения заболеваний, связанных с цилиопатиями - Google Patents
Способы лечения заболеваний, связанных с цилиопатиямиInfo
- Publication number
- EA202090850A1 EA202090850A1 EA202090850A EA202090850A EA202090850A1 EA 202090850 A1 EA202090850 A1 EA 202090850A1 EA 202090850 A EA202090850 A EA 202090850A EA 202090850 A EA202090850 A EA 202090850A EA 202090850 A1 EA202090850 A1 EA 202090850A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- animal
- agent
- ciliopathy
- treating
- exposed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
- A61K49/008—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion lipoprotein vesicle, e.g. HDL or LDL proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Dispersion Chemistry (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Раскрываются способы лечения заболевания, связанного с цилиопатией, включая введение субъекту, нуждающемуся в этом, эффективного количества соединения, которое нацелено по меньшей мере на один рецептор, сопряжённый с G-белком. Обеспечиваются способы идентификации терапевтических агентов для лечения заболевания, имеющего цилиопатию, в том числе создание модели цилиопатии на животных для тестирования предполагаемого терапевтического агента; введение нарушающего агента животному, воздействие на животное путем введения предполагаемого терапевтического агента, сравнение измеряемого фенотипа животного, которое подвергалось воздействию агента, с таковым животного, которое не подвергалось воздействию агента, и определение терапевтической мишени для лечения цилиопатии, если измеряемый фенотип животного, которое подвергалось воздействию агента, улучшается по сравнению с таковым у животного, которое не подвергалось воздействию агента.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762572051P | 2017-10-13 | 2017-10-13 | |
| PCT/US2018/055670 WO2019075369A1 (en) | 2017-10-13 | 2018-10-12 | METHODS OF TREATING DISEASES ASSOCIATED WITH CILIOPATHIES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202090850A1 true EA202090850A1 (ru) | 2020-07-16 |
Family
ID=64110108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202090850A EA202090850A1 (ru) | 2017-10-13 | 2018-10-12 | Способы лечения заболеваний, связанных с цилиопатиями |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210186985A1 (ru) |
| EP (1) | EP3694606A1 (ru) |
| JP (2) | JP2020536936A (ru) |
| KR (1) | KR20200070259A (ru) |
| CN (1) | CN111447973A (ru) |
| AU (1) | AU2018347460B2 (ru) |
| BR (1) | BR112020007006A2 (ru) |
| CA (1) | CA3078865A1 (ru) |
| EA (1) | EA202090850A1 (ru) |
| MX (1) | MX2020003682A (ru) |
| WO (1) | WO2019075369A1 (ru) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024074461A1 (en) * | 2022-10-03 | 2024-04-11 | Institut National de la Santé et de la Recherche Médicale | Use of inhibitors of the hippo signalling pathway for the treatment of chronic nephropathies |
| CN115807077B (zh) * | 2022-12-24 | 2023-06-27 | 湛江中心人民医院 | Ets1在制备诊断或治疗纤毛疾病产品中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6297769B2 (ja) * | 2009-02-02 | 2018-03-20 | クロモセル コーポレーション | 新規の細胞株および方法 |
| US20110081296A1 (en) * | 2009-09-24 | 2011-04-07 | Rutgers, The State University Of New Jersey | Systems and methods for identification of ciliopathy therapeutics |
| WO2015148566A1 (en) * | 2014-03-24 | 2015-10-01 | Duke University | Screening targets and compositions and methods for treatment of ciliopathy disorders |
-
2018
- 2018-10-12 KR KR1020207011486A patent/KR20200070259A/ko not_active Application Discontinuation
- 2018-10-12 EA EA202090850A patent/EA202090850A1/ru unknown
- 2018-10-12 MX MX2020003682A patent/MX2020003682A/es unknown
- 2018-10-12 EP EP18797307.8A patent/EP3694606A1/en active Pending
- 2018-10-12 JP JP2020520788A patent/JP2020536936A/ja active Pending
- 2018-10-12 CA CA3078865A patent/CA3078865A1/en active Pending
- 2018-10-12 WO PCT/US2018/055670 patent/WO2019075369A1/en unknown
- 2018-10-12 AU AU2018347460A patent/AU2018347460B2/en active Active
- 2018-10-12 CN CN201880068999.XA patent/CN111447973A/zh active Pending
- 2018-10-12 US US16/755,767 patent/US20210186985A1/en active Pending
- 2018-10-12 BR BR112020007006-8A patent/BR112020007006A2/pt not_active Application Discontinuation
-
2023
- 2023-08-04 JP JP2023128038A patent/JP2023159184A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020003682A (es) | 2020-12-11 |
| BR112020007006A2 (pt) | 2020-10-06 |
| WO2019075369A1 (en) | 2019-04-18 |
| AU2018347460A1 (en) | 2020-04-23 |
| CN111447973A (zh) | 2020-07-24 |
| JP2020536936A (ja) | 2020-12-17 |
| EP3694606A1 (en) | 2020-08-19 |
| JP2023159184A (ja) | 2023-10-31 |
| KR20200070259A (ko) | 2020-06-17 |
| CA3078865A1 (en) | 2019-04-18 |
| US20210186985A1 (en) | 2021-06-24 |
| AU2018347460B2 (en) | 2024-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123388T1 (el) | Υποκατεστημενου νικοτινιμιδιου αναστολεις της βτκ και παρασκευη αυτων και χρηση στη θεραπεια καρκινου, φλεγμονης και αυτοανοσης ασθενειας | |
| EA202090776A1 (ru) | Визуализирующие и радиотерапевтические агенты, нацеленные на фибробласт-активирующий белок-альфа (fapalpha) | |
| BR112015027682A2 (pt) | Uso de sobetirome no tratamento de doenças ou condições associadas com a desmielinização ou mielinização insuficiente | |
| BR112017009159A2 (pt) | métodos e biomarcadores para predizer a eficácia e avaliação de um tratamento com agonista de ox40 | |
| EA202190661A1 (ru) | Агонисты фарнезоидного х-рецептора для лечения заболевания | |
| EA201690212A8 (ru) | Способы лечения или профилактики офтальмологических патологических состояний | |
| BR112013027554A2 (pt) | "usos de compostos no tratamento de mal de alzheimer, doença de huntington, autismo e outros distúrbios" | |
| AR103782A1 (es) | ANTAGONISTAS DE INTEGRINA b7 Y MÉTODOS DE TRATAMIENTO DE LA ENFERMEDAD DE CROHN | |
| EA201890891A1 (ru) | Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение | |
| CL2017001756A1 (es) | Régimen de dosificación para antagonistas de madcam. | |
| MX2015012547A (es) | Tratamiento de una disfuncion cardiaca diastolica con un agonista del receptor trpv2. | |
| EA201591290A2 (ru) | Креноланиб для лечения пролиферативных расстройств, связанных с мутацией flt3 | |
| BR112018006866A2 (pt) | compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos | |
| UA124238U (uk) | Спосіб лікування раку молочної залози | |
| EA201791993A1 (ru) | Способы лечения протеинопатий | |
| EA202090850A1 (ru) | Способы лечения заболеваний, связанных с цилиопатиями | |
| BR112017025998A2 (pt) | inibidor de eixo igfbp3/tmem219, composição farmacêutica para uso no tratamento e/ou prevenção de diabetes, método para identificar um indivíduo em risco de desenvolver diabetes tipo 1 e/ou tipo 2 ou para monitorar a resposta a um tratamento terapêutico em um indivíduo e kit | |
| MX2020012613A (es) | Composiciones y usos de las mismas para el tratamiento de enfermedades o afecciones. | |
| EA201891007A1 (ru) | Нацеливание на формилпептидный рецептор 2/рецептор липоксина a(fpr2/alx) для лечения заболеваний сердца | |
| BR112022001270A2 (pt) | Compostos inibidores | |
| BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios | |
| EA201691656A2 (ru) | Терапевтические способы с применением норибогаина и родственных соединений | |
| EA201790352A1 (ru) | Терапевтическое лечение на основе анаморелина | |
| BR112018073419A2 (pt) | combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
| BR112018073396A2 (pt) | combinação de antagonistas, uso de uma combinação, método para o tratamento de desordens cognitivas, composto, método para o tratamento de doença de alzheimer e composição farmacêutica |